PACE Healthcare Capital is an early-stage venture capital firm focused on investing in digital health and health tech companies that have developed high impact solutions to critical healthcare challenges. Strategically headquartered in the Midwest, we leverage our decades of investing and operating experience across the healthcare ecosystem to support our entrepreneurs. By deploying financial capital and human capital, we help our them accelerate customer acquisition, attract top talent, and stay ahead with innovation.We focus on late Seed, Series A and B rounds

SMART2mrw is a healthcare innovation consultancy working with emerging life science and health technology companies to turn ideas into innovation and innovation into impact. We’ve got “grease under our fingernails” and are focused on providing answers not defining the problem. We are flexible, responsive, proactive and thought provoking and are embedded experts focusing on delivering results and building your capabilities. We’re with you as long as you need us and will be gone when you are ready.

Responsible for establishing effective relationships with investors and partners and executing all business and corporate development activities. In addition, lead the commercialization planning of moNATor®, Abreos’ first commercially available dose-monitoring test for multiple sclerosis patients being treated with Tysabri™ (natalizumab).

MATTER is a healthcare startup incubator, community nexus and corporate innovation accelerator. We help startups solve the right healthcare problems in the right ways and bring together health systems, industry executives, entrepreneurs and investors to learn, connect and collaborate. In addition, we help businesses define their challenges, identify solutions and innovate faster.

Built a transformative Go-To-Market model and operational plans for ITCA 650. Developed the infrastructure, talent, teams and capabilities needed to launch ITCA 650 and develop a new commercialization model.

Established the first Global Marketing function within Takeda including building a Global Market Access team and Global Customer Insights capability. Provided marketing and commercial leadership for brands through all stages of their life cycle for assets in a number of disease areas including; Cardiovascular, Metabolics, Neuroscience, Pain, Allergy and Respiratory, Immunology, Genitourinary and Gastrointestinal. Executed Takeda’s first biologic global launch of Entyvio (vedolizumab) for the treatment of Ulcerative Colitis and Crohn’s Disease.

Head of Commercial Development and Global Marketing for Pfizer's Global Primary Care Business Unit. Responsible for brands from proof-of-concept through loss of exclusivity, Global Market Analytics, Customer Insights and Japan / Korea Commercial Integration. In addition provide commercial leadership on Business Development opportunities, Portfolio Management and Marketing Excellence.Disease areas: Cardiovascular, Metabolics, Neuroscience, Pain, Allergy & Respiratory, Genitourinary, Gastrointestinal, Smoking Cessation and Women's Health.

Provided commercial leadership for Pfizer’s Infectious Disease and Oncology Therapeutic Areas. Responsible for establishing disease area strategies, driving commercial input to drug development and completing commercial evaluation of external development opportunities.

Responsible for EMEA HIV Business

Launched Tequin (gatifloxacin) antibacterial in US and International Markets Led the commercial development of novel anti-bacterial (garenoxacin) that drove input to clinical development program designed to maximize valueDesigned and implemented Global Brand Team operating model that ensured integration of regional, country and cross functional input into brand development strategy